Key Considerations For Launching Pharmaceutical Products In Emerging Markets
In light of growing revenue opportunities from emerging markets, we highlight tactics and successful examples for companies to leverage in overcoming challenges of low disease awareness and changing practice patterns.
You may also be interested in...
Takeda Pharmaceutical Co.'s $13.7 billion purchase of privately held Nycomed International Management is undoubtedly pricey, at over three times the Swiss group's 2010 revenues. But because it satisfies a number of strategic and financial imperatives, the deal - Takeda's largest ever - may be worth the cost.
One of the key take-aways from a wide-ranging hour-long panel discussion on emerging markets at Elsevier Business Intelligence's 20th Pharmaceutical Strategic Alliances meeting was the notion that drugmakers cannot implement a one-size-fits-all strategy when building a presence in important new markets. Participating in the forum were Mervyn Turner, PhD, chief strategy officer of Merck , Jean-Michel Halfon, president and general manager of Pfizer's emerging markets business unit, and Robin Arnold, a consultant with IMS Health.
Drug companies have their last chance to negotiate which documents and information Italy’s regulator, AIFA, will be entitled to request of them when they submit pricing and reimbursement applications.